Aytu BioPharma Prices Public Offering Of 1.37M Shares At $1.50 And 8.23M Prefunded Warrants At $1.4999, Expecting Up To $14.9M In Net Proceeds To Support EXXUA Commercialization And Corporate Operations

On June 5, 2025, Aytu BioPharma, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Lake Street Capital Markets, LLC, as underwriter (the "Underwriter"), relating to the public offering of 1,366,668 shares of the Company's common stock, par value $0.0001 per share ("Common Stock"), at a purchase price per share of Common Stock of $1.50 (the "Offering Price"), and 8,233,332 prefunded warrants in lieu of Common Stock ("Prefunded Warrants") at a purchase price per Prefunded Warrant of $1.4999, each of which enables the investor to purchase one share of Common Stock at an exercise price of $0.0001. Pursuant to the Underwriting Agreement, the Company granted the Underwriter a 30-day option to purchase up to an additional 1,440,000 shares of Common Stock at the Offering Price, less any underwriting discounts and commissions.

Net proceeds from the offering will be approximately $12.9 million (or approximately $14.9 million if the Underwriter exercises its option to purchase additional shares of Common Stock in full) after deducting the underwriting discounts and commissions and other estimated offering expenses payable by the Company. The Company intends to use the net proceeds of this offering for general corporate purposes, working capital and general and administrative expenses, and to execute on a transaction that will enable the Company to exclusively commercialize EXXUATM (gepirone) extended-release tablets.